May 19, 2011

Cancer Genetics Appoints Elizabeth A. Czerepak as Chief Financial Officer

Rutherford, NJ – May 18, 2011 – Cancer Genetics, Inc. (CGI), a life science company focused on personalized cancer medicine, today announced it has appointed Elizabeth A. Czerepak as Chief Financial Officer. In this role, Ms. Czerepak will lead the finance, clinical billing operations, human resources, and administrative support functions. She will report directly to Panna Sharma, President and CEO, and will be an officer of the Company.

“We’re fortunate to have Elizabeth join the management team at a time when CGI is growing through technology advancement, collaborations and partnerships,” said Panna Sharma, CEO of CGI. “Elizabeth’s experience in biotech finance, venture capital, business development and licensing will be instrumental as we pursue several avenues to commercialize molecular diagnostics products and laboratory services, and to evolve CGI into a leading personalized cancer treatment company. We’re pleased to welcome Elizabeth to the CGI team.”

Ms. Czerepak, 55, brings 28 years of industry experience to CGI. She is a founder of BIOptima Advisors, a consulting firm providing business development, strategic planning and clinical advisory services to biotechnology and pharmaceutical companies. Most recently, Ms. Czerepak was Managing Director at Bear, Stearns & Co.,later JP Morgan, where she founded Bear Stearns Health Innoventures (BSHI), a $212 million venture capital fund that led investments in thirteen biotechnology companies. From 1982 to 2000, Ms. Czerepak held senior positions in licensing, business development and finance at BASF Pharma, Hoffmann-La Roche and Merck & Co.

Ms. Czerepak earned an MBA from Rutgers University and graduated magna cum laude with a B.A. in Secondary Education from Marshall University. She is a member of Licensing Executives Society and serves on the Board of Directors of ToleRx, Inc.

# # #

About CGI
Based in of Rutherford, NJ, CGI was founded by Dr. R.S.K. Chaganti in 1999 and has become an emerging leader in personalized cancer treatment. CGI’s synergistic business model provides cancer-focused diagnostic testing services to leading oncologists, pathologists, hospitals, and academic centers as well as the development of next-generation diagnostic products that leverage CGI’s unique IP in molecular genetics and oncology. Products developed by CGI are revolutionizing the management and treatment of certain cancers while reducing healthcare costs. Information about the company can be found on the Internet at: www.cancergenetics.com.